Demographic Profile of Biologic Types of Ameloblatoma and Ameloblastic Carcinoma Seen in a Nigerian Population

Background- Ameloblastoma is a benign aggressive neoplasm of odontogenic epithelium characterized by local invasiveness, propensity for facial deformity, and a high rate of recurrence. This typical clinical picture characterizes the conventional clinical type. However, slight variations exist with other clinical types. Not all ameloblastoma behave this aggressively and it is important to distinguish between clinical types of ameloblastoma, as well as its clinically and histologically malignant counterpart, ameloblastic carcinoma, to be able to give appropriate diagnosis and treatment to patients.
Aim- The aim of this study is to analyse the demographic characteristics of the biologic types of ameloblastoma, as well as that of ameloblastic carcinoma, mostly seen in a Nigerian tertiary centre.
Methods- H & E sections and formalin-fixed paraffin embedded (FFPE) tissues of ameloblastoma and ameloblastic carcinoma histologically diagnosed between January 2000 and December 2011 were retrieved. The slides were reviewed for confirmation of histological diagnosis. The ameloblastoma cases were classified according to the 2022 WHO classification of odontogenic tumours into Conventional, Unicystic, and Peripheral biological types. Data was analysed with SPSS version 20.0.
Results- Ameloblastoma is more common in the third decade of life, having a mean age of 32±14.6 years, while ameloblastic carcinoma is more common in the fourth decade of life with median age of 33.5 years. Ameloblastoma is more common in males while ameloblastic carcinoma is more common in females. Of the biological types of ameloblastoma seen, Conventional ameloblastoma is more common than Unicystic type. Whereas the Conventional ameloblastoma peaked in the third decade of life, Unicystic ameloblastoma unusually peaked in the fourth decade of life with a mean of 35.2 (SD± 16.3) years. Mural type is the most common type of Unicystic Ameloblastoma in the series.
Conclusion- The knowledge of the demographic distribution of the biologic types of ameloblastoma, as well as ameloblastic carcinoma, in the Nigerian population is crucial for accurate clinical diagnoses that inform appropriate therapies.

Biologic types, Ameloblastoma, Ameloblastic carcinoma, Demography

1. Regezi JA, Scuibba J, Jordan C (Eds.). Odontogenic Tumors. Oral Pathology: Clinicopathologic Correlations. 5th ed. Saunders Elsevier; 2003:265–270. [Google Scholar] [Crossref]

2. Gruica B, Stauffer E, Buser D, Bornstein M. Ameloblastoma of the follicular, plexiform, and acanthomatous type in the maxillary sinus: a case report. Quintessence Int. 2003;34(4):311–314. [Google Scholar] [Crossref]

3. Junquera L, Ascani G, Vicente JC, Garcia-Consuegra L, Roig P. Ameloblastoma revisited. Ann Otol Rhinol Laryngol. 2003;112(12):1034–1039. [Google Scholar] [Crossref]

4. Ebenezer V, Ramalingam B. A cross-sectional survey of prevalence of odontogenic tumours. J Maxillofac Oral Surg. 2010;9(4):369–374. [Google Scholar] [Crossref]

5. Ladeinde AL, Ajayi OF, Ogunlewe MO, Adeyemo WL, Arotiba GT, Bamgbose BO, et al. Odontogenic tumors: a review of 319 cases in a Nigerian teaching hospital. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(2):191–195. [Google Scholar] [Crossref]

6. Fletcher DM (Ed.). Odontogenic Tumors. Diagnostic Histopathology of Tumors. 2nd ed. Churchill Livingstone; 2000:217–220. [Google Scholar] [Crossref]

7. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol. 2007;30(6):645–648. [Google Scholar] [Crossref]

8. Effiom OA, Odukoya O. Desmoplastic ameloblastoma: analysis of 17 Nigerian cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111(1):e27–e31. [Google Scholar] [Crossref]

9. WHO Classification of Tumours Editorial Board. Head and Neck Tumours [Internet]. 5th ed., vol. 9. Lyon (France): International Agency for Research on Cancer; 2022. [Google Scholar] [Crossref]

10. Ajagbe HA, Daramola JO. Ameloblastoma: a survey of 199 cases in the University College Hospital, Ibadan, Nigeria. J Natl Med Assoc. 1987;79(3):324–327. [Google Scholar] [Crossref]

11. Curi MM, Dib LL, Pinto DS. Management of solid ameloblastoma of the jaws with liquid nitrogen spray cryosurgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;84(4):339–344. [Google Scholar] [Crossref]

12. Olaitan AA, Adeola DS, Adekeye EO. Ameloblastoma: clinical features and management of 315 cases from Kaduna, Nigeria. J Craniomaxillofac Surg. 1993;21(8):351–355. [Google Scholar] [Crossref]

13. Adekeye EO. Ameloblastoma of the jaws: a survey of 109 Nigerian patients. J Oral Surg. 1980;38(1):36–41. [Google Scholar] [Crossref]

14. Ackermann GL, Altini M, Shear M. The unicystic ameloblastoma: a clinicopathological study of 57 cases. J Oral Pathol. 1988;17(9–10):541–546. [Google Scholar] [Crossref]

15. Olaitan AA, Adekeye EO. Unicystic ameloblastoma of the mandible: a long-term follow-up. J Oral Maxillofac Surg. 1997;55(4):345–348. [Google Scholar] [Crossref]

16. Li TJ, Kitano M, Arimura K, Sugihara K. Recurrence of unicystic ameloblastoma: a case report and review of the literature. Arch Pathol Lab Med. 1998;122(4):371–374. [Google Scholar] [Crossref]

17. Rosenstein T, Pogrel MA, Smith RA, Regezi JA. Cystic ameloblastoma—behavior and treatment of 21 cases. J Oral Maxillofac Surg. 2001;59(11):1311–1316. [Google Scholar] [Crossref]

18. Regezi JA. Odontogenic cysts, odontogenic tumors, fibro-osseous, and giant cell lesions of the jaws. Mod Pathol. 2002;15(3):331–341. [Google Scholar] [Crossref]

19. Owosho AA, Ladeji AM, Adebiyi KE, et al. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas. Eur Arch Otorhinolaryngol. 2021;278(8):3065–3071. [Google Scholar] [Crossref]

20. Kaye FJ, Ivey AM, Drane WE, Mendenhall WM, Allan RW. Clinical and radiographic response with combined BRAF-targeted therapy in stage IV ameloblastoma. J Natl Cancer Inst. 2015;107(1):378. [Google Scholar] [Crossref]

21. Tan S, Pollack JR, Kaplan MJ, Colevas AD, West RB. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):e5–e7. [Google Scholar] [Crossref]

22. Faden DL, Algazi A. Durable treatment of ameloblastoma with single-agent BRAF inhibitor. J Natl Cancer Inst. 2017. [Google Scholar] [Crossref]

23. Fernandes GS, Girardi DM, Bernardes JPG, Fonseca FP, Fregnani ER. Clinical benefit and radiological response with BRAF inhibitor in recurrent ameloblastoma. BMC Cancer. 2018;18(1):887. [Google Scholar] [Crossref]

24. Broudic-Guibert M, Blay JY, Vazquez L, et al. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation. J Med Case Rep. 2019;13(1):245. [Google Scholar] [Crossref]

25. Philipsen HP, Reichart PA, Nikai H, Takata T, Kudo Y. Peripheral ameloblastoma: biological profile based on 160 cases. Oral Oncol. 2001;37(1):17–27. [Google Scholar] [Crossref]

26. Gardner DG. Peripheral ameloblastoma: a study of 21 cases. Cancer. 1977;39(4):1625–1633. [Google Scholar] [Crossref]

27. Agbaje JO, Adisa AO, Petrova MI, et al. Biological profile of ameloblastoma and its location in the jaw in 1246 Nigerians. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;126(5):424–431. [Google Scholar] [Crossref]

28. Hendra FN, Van Cann EM, Helder MN, et al. Global incidence and profile of ameloblastoma: a systematic review and meta-analysis. Oral Dis. 2020;26:12–21. [Google Scholar] [Crossref]

29. Akinshipo AW, Sivaramakrishnan G, Enwuchola J, et al. Ameloblastoma in African populations: a comprehensive analysis of 371 cases. Head Neck Pathol. 2025;19(1):2. [Google Scholar] [Crossref]

30. Intapa C. Prevalence and clinical features of ameloblastoma in Southeast Myanmar and Northern Thailand. J Clin Diagn Res. 2017;11(1):ZC102–ZC106. [Google Scholar] [Crossref]

31. Vila S, Oster RA, James S, et al. Retrospective analysis of 129 ameloblastoma cases. J Racial Ethn Health Disparities. 2025;12:1612–1620. [Google Scholar] [Crossref]

32. Eversole LR, Leider AS, Strub D. Radiographic characteristics of cystogenic ameloblastoma. Oral Surg Oral Med Oral Pathol. 1984;57(5):572–577. [Google Scholar] [Crossref]

• “Improving Laboratory Operations and Patient Care through Total Laboratory Automation”
• Prognostic Significance of Reck in Ameloblastoma and Ameloblastic Carcinoma
• “From Gut to Gonads: A Rare Journey of Jejunal Neuroendocrine Tumor to the Testis”